Unpublished Study Pegs Cost Of New Drug At $231 Million

BOSTON - An unpublished study that examines the cost of bringing a new drug to market has revived debate over whether data should be released to the public prior to peer review. The study, which cites a figure that is nearly twice as high as previous estimates, is already being used in ongoing discussions over federal policies on drug pricing and the investment in research by the pharmaceutical industry. The just-completed analysis by the Tufts University Center for the Study of Drug Developme

| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

BOSTON - An unpublished study that examines the cost of bringing a new drug to market has revived debate over whether data should be released to the public prior to peer review. The study, which cites a figure that is nearly twice as high as previous estimates, is already being used in ongoing discussions over federal policies on drug pricing and the investment in research by the pharmaceutical industry.

The just-completed analysis by the Tufts University Center for the Study of Drug Development reported that it takes 12 years and the equivalent of $231 million (in 1987 dollars) to bring a single new prescription drug to market. The cost cited is more than double that of 10 years ago, even after adjusting for inflation, and the length of time is two years longer than previously judged. About half of the total consists of "time costs," or money lost by forgoing ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Jack Jackson

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo